Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 5,432 shares at $75.64 ($413K) on 2025-11-17, disclosed to the SEC on 2025-11-19.
Scheduled sale ($413k) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $75.64 | 1,843 | $139K | 33.8% |
| 2 | $75.64 | 1,843 | $139K | 33.8% |
| 3 | $76.53 | 777 | $59K | 14.4% |
| 4 | $76.53 | 777 | $59K | 14.4% |
| 5 | $77.18 | 192 | $15K | 3.6% |
| Total | $75.95 avg | 5,432 |
| $413K |
| 100% |
| Filing → |
| PTCT | SELL | 2026-08-19 | $204K | — | Filing → |
| PTCT | SELL | 2026-07-08 | $432K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |